On 2020-05-05 18:47:07, user Taekjip Ha wrote:
Thank you very much for sharing your interesting manuscript!<br />
We used your preprint as one of the journal club papers in the Single<br />
Molecule & Single Cell Biophysics course for graduate students of Johns<br />
Hopkins University during the Covid-19 lockdown. Students also practiced peer<br />
reviews as the final assignment. I am submitting their formal reviews here <br />
and hope you find them useful.
Taekjip Ha
Reviewer 1.
Summary of Evaluation:
Here, Janissen et al. describe a novel mechanism by which viral RNA-dependent<br />
RNA polymerases (RdRp) undergo induced template switching during RNA synthesis.<br />
These template switching reactions can be intermolecular, resulting in<br />
homologous recombination, or intramolecular, resulting in copy-back synthesis.<br />
Typically, RNA-analogues introduced as antivirals result in chain termination or<br />
lethal mutagenesis, but non-single-molecule experiments may have inappropriately<br />
classified instances of template switching as termination and would not have<br />
been detected. Therefore, by utilizing a single-molecule approach, the authors<br />
are able to analyze RdRp pauses, backtracking, and copy-back synthesis, which<br />
they ultimately determine can be induced by the addition of a<br />
pyrazine-carboxyamide antiviral nucleotide with an unconfirmed mechanism.<br />
Overall, the paper makes a compelling argument for viral RdRp backtracking and<br />
recombination induction as a third mechanistic class of antivirals, although a<br />
few components of the experimental design and conclusions may require further<br />
experimentation. The use of a single-molecule approach to probe the in vitro<br />
dynamics of RdRp synthesis, though previously described, proves powerful in<br />
elucidating how reversals and recombination, particularly of EV-A71 RdRp, may<br />
occur. Further, the data suggests that the recently approved antiviral T-1106<br />
may be acting through this recombination mechanism, which has not been<br />
previously described. <br />
The article benefits from well-structured and balanced figures that successfully<br />
convey the data at hand in a straight-forward manner. Although occasionally<br />
verbose (discussion) and short at others (conformational dynamics results), the<br />
paper’s writing successfully conveys the importance of the findings and supports<br />
the findings with appropriate literature references. The work itself tells a<br />
fairly complete story with logical transitions and progression between<br />
experiments and conclusions. The paper is overall of high quality, though<br />
further controls and validation may be necessary to fully substantiate some<br />
claims as detailed below. Though not necessarily field-defying, the paper<br />
introduces the possibility of novel mechanisms of antiviral therapeutics that<br />
could serve to push human health forward and is deserving of high recognition.
Summary of Data:
To elucidate the mechanism by which template switches occur, the authors first<br />
utilized a magnetic tweezers assay to determine the elongation or retraction of<br />
an RNA-RNA complex that served as a read-out of RdRp synthesis or<br />
backtracking/reversal, respectively. Using the RdRp from EV-A71, a virus more<br />
prone to recombination than the RdRp of their previous work (poliovirus, PV),<br />
the authors show instances of RdRp backtracking and magnetic bead retraction,<br />
which they conclude is due to a template switching mechanism that leads to<br />
copy-back RNA synthesis and formation of defective viral RNA products. Utilizing<br />
an EV-A71 RdRp variant analogous to a previously described mutation in PV RdRp<br />
that impairs recombination, the authors showed that while replication was not<br />
impaired, the EV mutant showed a 100-fold decrease in viral titer in an assay<br />
that required recombination for successful viral replication. The mutant virus<br />
was also highly attenuated in a mouse model relative to WT, in agreement with<br />
previous work that PV RdRp requires recombination to cause disease in a mouse<br />
model. <br />
Mutant EV-A71 RdRp showed increased pause probability and pause duration, but<br />
decreased reversal probability compared to WT, which suggested a decreased<br />
ability to backtrack in the mutant. The orthologous PV mutant showed similar<br />
results. Using molecular dynamics simulations, the authors showed that the<br />
EV-A71 mutant had a smaller RNA-binding channel compared to WT, with the mutant<br />
channel more closely resembling the PV RNA-binding channel size. The dynamics<br />
data corroborates a mechanism by which EV-A71 RdRp, but neither its mutant nor<br />
PV RdRp, has a binding channel large enough to accommodate copy-back RNA<br />
synthesis. <br />
Finally, the authors utilized the antiviral ribonucleotide T-1106, a drug with<br />
inconsistent mechanistic understanding, in cell-based viral recombination<br />
experiments. The WT EV-A71 RdRp showed increased pausing, pause duration, and<br />
reversal probability in the presence of T-1106. In the recombination assay,<br />
T-1106 increased recombination in WT EV-A71 but not the recombination defective<br />
mutant. The authors also show that the mutant RdRp does not lead to viral<br />
resistance to T-1106.
Major Issues:
• In the single molecule assay, the retraction of the magnetic bead is<br />
attributed to copy-back synthesis. Though a plausible mechanism, the main<br />
evidence of this mechanism is of similar kinetics between elongation and<br />
copy-back. While a valid assumption given the data shown, further validation is<br />
required to definitively say that copy-back synthesis is occurring. The most<br />
obvious way to validate this is through the determination of the RNA products.<br />
Though it may be difficult to detect RNA products in these single molecule<br />
experiments, this information is crucial to confirm that copy-back synthesis is<br />
indeed occurring, especially since this mechanism is invaluable to conclusions<br />
drawn throughout the paper.
• The in vitro experiments in this paper exclusively look at intramolecular<br />
template switching (though this must be further validated as stated above).<br />
However, most if not all of the cell-based assays exclusively assay for<br />
intermolecular recombination (luciferase donor assay). Though the correlation<br />
between the two types of recombination are believable, validating that<br />
intermolecular recombination trends hold in vitro and that intramolecular trends<br />
hold in the cell-based assays is a crucial control. Without this data, the<br />
mechanistic conclusion of copy-back and recombination sharing an intermediate is<br />
jeopardized.
Minor Issues:
• The paper would benefit from greater elaboration on the effects of defective<br />
viral genomic products on viral replication to provide context for the activity<br />
of the purported new antiviral mechanistic target. What is known about defective<br />
viral genomic products?
• In the T-1106 assays, a 400µM T-1106 concentration is the only concentration<br />
that significantly increased recombination. This is not elaborated in the paper.<br />
Would you not expect higher concentrations to also have increased recombination?
• The flow of the paper is occasionally interrupted by terse, short sentences<br />
and the occasional grammatical error. Luckily, this is a bioRxiv and these are<br />
easily fixed prior to peer review.
Reviewer 2.
Summary: <br />
Janissen et al describe a third mechanistic class of antiviral ribonucleotides<br />
that utilize RdRp template-switching reactions, an interesting topic that is<br />
highly relevant today and can be especially appreciated in the context of the<br />
recent COVID-19 pandemic. They first demonstrate the need for new broad-spectrum<br />
antiviral therapies and identify viral polymerases as a powerful target, placing<br />
special emphasis on RNA-dependent RNA polymerases (RdRp). The currently approved<br />
antiviral nucleotides fall into two functionally distinct mechanistic classes;<br />
they are either chain terminators that stop nucleic acid synthesis or lethal<br />
mutagens which increase mutational load on the viral genome. However, these<br />
often have off target effects which lead to the emersion of a new class of<br />
antiviral nucleotides known as the favipiravir (T-705) class which requires the<br />
cellular nucleotide salvage pathway. Within this class, the nucleoside analog,<br />
T-1106, has high efficacy but its mechanism of action is unknown which prevents<br />
FDA approval. This work is an expansion of a previous study that used a magnetic<br />
tweezers approach to illustrate that pausing and backtracking of the elongating<br />
Poliovirus (PV) RdRp was enhanced by incorporation of T-1106 into the nascent<br />
RNA. They noted that traditional polymerase elongation assays would have missed<br />
the backtracked state, which they believe provides evidence for a third<br />
mechanistic class of antiviral ribonucleotides that rely on RdRp mediated inter-<br />
(homologous recombination) or intramolecular (copy back RNA synthesis) template<br />
switching. <br />
In hopes to elucidate this mechanism, Janissen et al hypothesized that T-1106<br />
induced backtracking generates a free 3’ single-stranded RNA end, which<br />
functions as an intermediate for template switching and results in a reduction<br />
of viral replication. In this work they 1) characterized the recombination prone<br />
Enterovirus (EV) RdRp in their magnetic tweezers system, 2) developed a<br />
recombination deficient EV RdRp (Y276H), 3) briefly analyzed the structures of<br />
WT and mutant PV and EV RdRps in silico, and 4) explored the effect of T-1106 on<br />
the WT and mutant RdRps. They used the same magnetic tweezers approach is in the<br />
previous study to demonstrate that EV RdRp pauses similarly to what was seen for<br />
PV RdRp, which is inversely correlated with nucleotide concentration. Their more<br />
interesting finding was that unlike PV RdRp, EV RdRp displays reversals. They<br />
proposed a probable reversal mechanism in which EV RdRp pausing leads to<br />
backtracking that produces a free single stranded 3’ RNA end which can serve as<br />
a primer for copy-back RNA synthesis as observed by a decrease in bead height.<br />
To connect reversals with recombination they generated a recombination deficient<br />
RdRp mutant, Y276H, which is orthologous to the known PV mutant, Y275H.<br />
Replication, plaque formation, and genome amount of virus titer were determined<br />
to be similar for WT and Y276H EV RdRp. They confirmed that this mutant was<br />
recombination deficient and showed that oral inoculation of EV Y276H resulted in<br />
attenuation of virulence in hSCARB2 mice compared to WT. Y276H had increased<br />
pausing, decreased processivity, and decreased reversals which were still<br />
pause-dependent. This finding was puzzling but was proposed to be due to<br />
increased stability of Y276H on the free 3’ RNA end, rendering it unavailable<br />
for reversals. Similar results were observed for the PV RdRp Y275H. In hopes to<br />
explain why EV RdRp can reverse but not PV RdRp and the impacts of the mutations<br />
they superimposed the structures and conducted molecular dynamics simulations.<br />
They concluded that PV had the smallest RNA channel which was similar to EV<br />
Y276H and that EV WT RdRp had the largest channel, enabling it able to undergo<br />
copy-back RNA synthesis. Finally, they explored the effect of T-1106 on EV RdRp<br />
template switching, which was shown to increase dwell time, reduce processivity,<br />
increase pause probability and duration, and increase reversal probability, all<br />
of which were claimed to be reflective of intramolecular template switching.<br />
They concurrently assessed T-1106’s effect on PV RdRp which was reflective of<br />
intermolecular template switching. They therefore concluded that antiviral<br />
ribonucleotides lead to increased backtracking and recombination, in which<br />
recombined products are not replication-competent and thus lead to a decrease in<br />
virulence. Most of the claims in this paper are substantiated by data, however,<br />
there are some major and minor flaws outlined below that need to be addressed<br />
prior to acceptance. A revised version of this paper would be suitable. <br />
General Feedback:<br />
Overall, this paper provides compelling evidence that RdRps display pausing and<br />
backtracking behavior. Their magnetic tweezers platform allows for single<br />
molecule analysis of the RdRps, which to my knowledge, has not been done before<br />
besides through their previous paper. The existence of a third mechanistic class<br />
of antiviral ribonucleotides is substantiated by their data, however, they only<br />
briefly addressed T-1106. The majority of the paper is spent characterizing EV<br />
RdRp in their magnetic tweezers system, with only one figure dedicated to T-1106<br />
effects. It may be more beneficial to split this paper in two, with one paper<br />
focusing on characterizing EV RdRp and comparing it to PV RdRp and the other<br />
determining the effects of T-1106, especially considering the T-1106 experiments<br />
that must be done to confirm its viability as an antiviral. Additionally, to<br />
convince the existence of an entire third mechanistic class, the favipiravir<br />
class of antiviral ribonucleotides should all be analyzed in their system. In<br />
general, the paper has an acceptable and organized flow, with only minor<br />
adjustments necessary (see minor issues). The experiments appear reproducible<br />
and robust. Their work in PV and EV RdRp recombination is mainly confirmatory,<br />
however, their platform allows for analyzation of this process at the<br />
single-molecule level which reveals novel insight into the mechanism. There are<br />
a few major issues that need to be addressed, outlined below, to support this<br />
finding and complete the paper. The discussion of the paper is also repetitive<br />
and should be edited to be more concise.
Major Issues:
The article did not discuss the intrinsic ability of RdRps to undergo template<br />
switching, which they extensively showed in their assays. If recombination and<br />
copy-back synthesis are intrinsic why would these be a valuable target as an<br />
antiviral? Is there a specific level or cut off where too much recombination<br />
becomes detrimental? I would like to see an assay in which they determine the<br />
level of recombination necessary to decrease virulence.
I would like to see more virulence studies, why didn’t they treat the hSCARB2<br />
mice with T-1106? This should be conducted to directly address T-1106 efficacy<br />
both in the context of WT and Y276H EV RdRp treated mice.
While the single molecule experiments demonstrate copy-back synthesis<br />
(intramolecular template switching) the cell-based experiments exclusively<br />
quantify homologous recombination (intermolecular template switching). This<br />
paper should contain an experiment that directly quantifies copy-back synthesis<br />
in a cellular context. Since copy back RNA synthesis should generate hairpins,<br />
RNA seq could be conducted to determine if sequences with hairpin-forming<br />
properties are enhanced in cells infected with EV RdRp and treated with T-1106<br />
compared to WT.
The magnetic tweezers approach was also unable to directly quantify<br />
intermolecular template switching. If possible, another template could be<br />
introduced to assay if pausing, and thus no change in bead height, becomes<br />
indefinite, which could indicate that the RdRp has left the initial template.
They claim that T-1106 has no effect on EV Y276H RdRp, but they show a<br />
significant reduction of recombination at higher doses (100-fold, figure 6H), so<br />
the data does not substantiate their claim.
Bar graphs are no longer an acceptable form of data presentation, these figures<br />
should be converted to dot plots to show data variability and illustrate<br />
replicates.
Is there a way to generate a mutant that has a greater propensity for<br />
recombination? If so, this would allow for a direct analysis of whether<br />
increasing recombination leads to decreased virulence. Another way to address<br />
this question would to be comparing PV and EV virulence, especially in a mouse<br />
model, since EV RdRp is more recombination prone.
Minor Issues:
This pausing-backtracking phenomenon was shown in both their previous work and<br />
in this paper, however, it was not confirmed through the use of other methods.<br />
Confirming the pausing phenomenon through other methods would be beneficial,<br />
perhaps using nanopore sequencing and/or single molecule tracking of the RdRp in<br />
cells to elucidate kinetic rates and interaction dynamics.
The structure and dynamics information seems out of place and is not very<br />
informative. This figure may be better suited at the beginning of the paper, or<br />
may not be needed at all, to describe the structural differences between PV and<br />
EV RdRps, and the greater propensity for EV RdRp recombination. It could later<br />
be mentioned that the mutants display pore sizes similar to PV RdRp which could<br />
be shown in a supplementary figure. These data show a smaller channel width for<br />
Y276H compared to WT EV RdRp. How could a smaller channel width affect<br />
backtracking ability, especially since PV and EV RdRps both display backtracking<br />
ability? How could this relate to the function of an antiviral ribonucleotide,<br />
does the nucleotide interfere with pore interactions? These questions are not<br />
adequately addressed and would contribute to the paper. Additionally, would a 4<br />
Å difference be sufficient to yield the PV RdRp unable to accommodate a three<br />
stranded intermediate at the time of initiation?
They did not hypothesize as to why 400 uM T-1106 concentration had the optimal<br />
response in their recombination assay. This should be addressed.
Determining the molecular basis for the reduced recombination capabilities of<br />
the recombination deficient RdRps would be beneficial but may be the grounds for<br />
a separate paper. For example, how might the Y275(6)H mutation be stabilizing<br />
the polymerase and reducing recombination?
Recommendation: <br />
I recommend revision of this article before acceptance in which the major and<br />
minor issues are addressed.
Reviewer 3.
The search for efficacious anti-viral therapeutics has become prominent in<br />
light of the recent coronavirus outbreak, with the RNA polymerase being a common<br />
target. A recent class of pyrazine carboxamide antiviral nucleotide and its<br />
analogs have shown promise, but there is ambiguity in the mechanism of action.<br />
It has been shown to increase backtracking during elongation for the poliovirus<br />
(PV) RNA-dependent RNA polymerase (RdRp), which may free the nascent 3’ end and<br />
allow for a template switch and recombination, producing inviable viral genome.<br />
This study used the more recombination-prone enterovirus (EV) RdRp to establish<br />
this connection between backtracking and recombination using a magnetic tweezers<br />
platform.<br />
The magnetic bead in this assay is tethered to a surface with ssRNA, and<br />
annealed to it is a template with a hairpin serving as a primer for the RdRp. As<br />
the RdRp polymerizes, the annealed RNA is displaced from the tethered RNA. At<br />
forces of >8pN, this causes the tethered RNA to lengthen, which is monitored by<br />
observing the height of the bead. This simple and highly informative assay<br />
showed that the EV RdRp is able to reverse, likely from the freed nascent 3’ end<br />
annealing to and elongating off itself and allowing reannealing to the template<br />
RNA. <br />
They then generated an EV mutant (Y276H) orthologous to the recombination<br />
deficient Y275H PV mutant and used a clever cellular assay with a gene construct<br />
reporting on recombination ability to show it is also recombination deficient,<br />
and also less deadly. This assay leaves non-recombined genomes unable to produce<br />
virus and expressing luciferase, and recombinants are viable and have low<br />
reporter output.<br />
To connect recombination ability and reversals, this mutant was tested for its<br />
ability to backtrack using the magnetic bead assay, and while it showed<br />
increased pausing, it showed decreased backtracking and reversals. To test if<br />
this was due to stabilization of the 3’ nascent RNA freed with the WT, they<br />
evaluated each RdRp in an in vitro RNA synthesis assay and found the mutant had<br />
a slower nucleotide incorporation rate. This same assay was performed with the<br />
PV WT and mutant RdRp to show similar results, but they importantly note that PV<br />
does not undergo reversals.<br />
Next the authors looked to the structure and dynamics of the PV and EV WT and<br />
mutant enzymes for insight into the mechanism of backtracking and recombination.<br />
They did not find obvious differences in crystal structure between EV and PV or<br />
between EV WT and mutant model. From here they did a lot of molecular dynamics<br />
simulations that I don’t fully understand, but they essentially tracked the<br />
distance between two residues within the RNA tunnel of the EV WT, EV mutant, and<br />
PV WT RdRps. Interestingly, the average distance was largest in the EV WT RdRp,<br />
smallest for PV WT, and the EV mutant was in between (but closer to PV). This is<br />
good suggestive data to show for the implications of RNA tunnel width for<br />
reversal ability, but they make no bold claims.<br />
In their last set of experiments, the authors again used the magnetic bead<br />
assay to assess EV RdRp movement but with the T-1106 drug. Unlike the<br />
recombinant deficient mutant, the drug caused a decrease in pausing and an<br />
increase in reversals. When the cellular recombination assay was applied with<br />
the WT EV RdRp and with the T-1106 drug was administered, there was an increase<br />
in recombinant-proficient plaque formation and a decrease in<br />
recombination-dependent reporter protein output. When the drug was applied to<br />
the mutant RdRp in the recombination assay, there was no activity to suggest<br />
that recombination was taking place.<br />
In supplementary Figure 6 the authors tested the sensitivity of each the EV WT<br />
and mutant RdRp to a titration of T-1106 concentrations. This was a great assay<br />
to perform, as it shows that even as the virus accumulates mutations in the<br />
polymerase the drug remains proficient. However, the sensitivity of the mutant<br />
to the drug is surprising since the drug was shown to cause no significant<br />
increase in the recombination ability of the mutant polymerase. While not stated<br />
explicitly, this could be addressed in the model posed in figure 6K as the<br />
aborted RNA synthesis.<br />
The model proposed from these data shows a logical conclusion drawn about how<br />
the drug is functioning on the polymerase, and the data were overall extremely<br />
well articulated. The experiments were mostly well described and straightforward<br />
while also being innovative and informative. This could be valuable information<br />
in drug development and testing for anti- RNA viral therapeutics.
Major points<br />
• Figure 2B and F: why is the mutant about equal to WT in the plaque assay, but<br />
has a significantly higher survival rate in vivo? You mention this is consistent<br />
with PV, but propose no reason.<br />
• Figure 3G and 4G: Mechanistically, why does a decreased rate of nucleotide<br />
incorporation correspond to an increase in polymerase stability?<br />
• Figure 6H: I would have liked to see the magnetic bead assay for the T-1106<br />
drug applied to the EV RdRp mutant.<br />
• Supplementary Figre 6: How is it that the mutant can still be so sensitive to<br />
the drug? It should maybe be discussed that the T-1106 drug is inhibiting some<br />
other property of the enzyme that leads to recombination as well as normal<br />
function.
Minor points<br />
• Figure 4: Why was the magnetic bead assay performed for the PV WT and mutant<br />
RdRp?<br />
• Why do you think PV RdRp doesn’t undergo reversals? Perhaps something to do<br />
with the RNA tunnel width?<br />
• Figure 5: What are the next experiments that should be done to explore the<br />
structure/dynamics? Is the tunnel width a potential factor in reversal ability?<br />
• There should be a sentence clarifying that the cellular recombination assay<br />
used in Figure 6 is the same as the one in Figure 2.